ANN ARBOR, Mich.
, Dec. 9, 2010
/PRNewswire/ -- Terumo Cardiovascular Systems has
announced the introduction of the VirtuoSaph® Plus Endoscopic Vessel Harvesting System following clearance by the U.S. Food and Drug Administration (FDA).
(Logo: http://photos.prnewswire.com/prnh/20041217/DEF008LOGO )
Based on the successful platform of the VirtuoSaph Endoscopic Vein Harvesting System, the VirtuoSaph Plus system is optimized for conduit quality during coronary artery bypass graft surgery and peripheral artery bypass graft procedures. It uses simultaneous cut-and-seal technology while minimizing thermal spread(1). An independent study by the University of Michigan found that the use of the VirtuoSaph EVH system resulted in zero thermal spread in a large number of vessel samples(1).
The VirtuoSaph Plus system provides an endoscopic approach to vessel harvesting. The system provides the cardiac surgery team with a device that is ergonomically designed and easy to use. With targeted energy delivery away from the vessel, spot cautery and an open CO2 delivery design, the VirtuoSaph Plus system consistently delivers bypass grafts with a new standard of care.
Supported by Terumo's established team of dedicated EVH clinical specialists and training centers, the VirtuoSaph Plus system provides a new level of confidence in conduit quality to the cardiac surgery team.
The VirtuoSaph Plus system will be marketed by Terumo Cardiovascular Systems in the United States and by Terumo companies around the world.
About Terumo Cardiovascular Systems Corporation
Terumo Cardiovascular Systems Corporation is a global manufacturer and marketer of medical devices for cardiac and vascular surgery. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is a subsidiary of Terumo Corporation of Japan. For more information, visit www.terumo-cvs.com.
About Terumo Corporation
Terumo Corporation is a premier global medical company with 2009 annual sales in excess of $3 billion and more than 13,000 employees. Terumo Corporation and its group companies develop, manufacture, and market a wide range of medical products including cardiac assist devices, vascular grafts, endovascular stent grafts, and interventional catheters and stents.
Terumo Cardiovascular Systems, along with its sister companies, Vascutek, Ltd. and Terumo Heart, Inc., embodies Terumo Corporation's commitment to advancing the treatment of cardiovascular disease.
Terumo Cardiovascular Systems
6200 Jackson Road
Ann Arbor, MI 48103
1 Data on file and awaiting publication
SOURCE Terumo Cardiovascular Systems